Blinatumomab, which recently completed clinical trials and has won approval from the FDA, is a drug designed to treat acute ...

Blinatumomab (Blincyto, Amgen) is indicated for 'the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor leukaemia ALL in the consolidation phase'. The ...

Bargou et al. assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non-Hodgkin lymphoma who relapsed after standard treatments.

SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the bispecific T-cell engager ...